Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
By Felix Chinguwo A two-year program in Malawi aims to educate people, especially men and boys, about HIV, reduce transmission of the virus, help people to […]
CDC announces publication of TB treatment trial results showing four month regimen as effective as six month
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
By Amir M. Mohareb, MD, Louise C. Ivers, MD, MPH, Rajesh T. Gandhi, MD, and Shahin Lockman, MD, MSc As the U.S. convenes a global COVID-19 […]